When we look at the treatment of low testosterone and performance enhancement, the two primary purposes of testosterone use and the two primary methods by-which the effects of testosterone are noted we see there are many overlapping similarities. Truly the only difference in performance enhancement is the doses are higher there by the effects themselves are enhanced. To receive the positive effects of testosterone beyond what you naturally produce it really doesnt matter which form you acquire; Testosterone- Cypionate , Testosterone- Enanthate , Testosterone- Propionate , mixtures such as Sustanon -250 and Omnadren or any other form you can think of, they all contain the same identical testosterone hormone. In the end you simply need the hormone and once you have adequate levels to even beyond you will function and thrive to your desired and needed level; this much is assured.
Common (1% to 10%): Sinusitis, nasopharyngitis, upper respiratory tract infection , bronchitis
Uncommon (% to 1%): Cough, dyspnea, snoring, dysphonia
Rare (less than %): Pulmonary microembolism (POME) (cough, dyspnea, malaise, hyperhidrosis, chest pain, dizziness, paresthesia, or syncope) caused by oily solutions
Frequency not reported: Sleep apnea
Postmarketing reports: Chest pain, asthma , chronic obstructive pulmonary disease , hyperventilation, obstructive airway disorder, pharyngeal edema, pharyngolaryngeal pain, pulmonary embolism , respiratory distress, rhinitis , sleep apnea syndrome [ Ref ]
Testim® was evaluated in a randomized multicenter, multi-dose, active and placebo controlled 90-day study in 406 adult males with morning testosterone concentrations ≤ 300 ng/dL. The study was double-blind for the doses of Testim and placebo, but open label for the non-scrotal testosterone transdermal system. During the first 60 days, patients were evenly randomized to Testim 50 mg, Testim 100 mg, placebo gel, or testosterone transdermal system. At Day 60, patients receiving Testim were maintained at the same dose, or were titrated up or down within their treatment group, based on 24-hour averaged serum testosterone concentration obtained on Day 30.